Lung Cancer

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to identify patients with RET fusion–positive non¬–small lung cancer who are candidates to receive the recently approved targeted therapy pralsetinib.

Anne Chiang, MD, PhD, discusses the management of ​immune-related adverse effects in lung cancer. 

A multi-year, multi-study research collaboration between Daiichi Sankyo and Gustave Roussy Cancer Center will support the clinical, translational, and preclinical evaluation of 2 of the company’s lead antibody-drug conjugates: DS-1062 in advanced non–small cell lung cancer, and patritumab deruxtecan in metastatic breast cancer.

Kartik Konduri, MD, discusses remaining sequencing challenges in ALK-positive non–small cell lung cancer.

Under a draft recommendation proposed by the US Preventive Services Task Force, individuals who are at a high risk for developing lung cancer because of their smoking history would begin annual screening with low-dose computed tomography at aged 50 years.

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

The FDA has approved pralsetinib for the treatment of patients with metastatic, RET fusion–positive non-small cell lung cancer.

Naiyer A. Rizvi, MD, discusses the utility of fam-trastuzumab deruxtecan-nxki  in non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses remaining challenges in non–small cell lung cancer.

Capmatinib continued to elicit a significant, durable responses in patients with metastatic non–small cell lung cancer whose tumors harbor a MET exon14 skipping mutation.

Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.

The RET inhibitor selpercatinib was shown to have durable efficacy with mostly low-grade adverse effects in patients with RET fusion–positive non–small-cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the evolution of targeting HER2 in lung cancer.

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non​–small cell lung cancer.

Nathan Pennell, MD, PhD, discusses the evolution of targeted therapies in the field of non–small cell lung cancer.

Edward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.

Narjust Duma, MD, discusses the importance of mitigating racial disparities in lung cancer research. 

Join us to learn more about how to navigate the new role of immunotherapy in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer on Wednesday, October 28, 2020 at 8:00 PM EDT.

Ticiana A. Leal, MD, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer.